Serpasil-apresoline

   
Google
 
Web NewDrugInformation.com

Serpasil-apresoline


Drug - Serpasil-apresoline
The trade name of the product as shown on the labeling.

Dosage - TABLET; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Hydralazine Hydrochloride; Reserpine
Multiple ingredients are in alphabetical order.

Strength - 50MG;0.2MG
The potency of the active ingredient(s), Hydralazine Hydrochloride; Reserpine. May repeat for multiple part products.

Applicant - NOVARTIS
The firm name holding legal responsibility for Serpasil-apresoline. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 009296
The FDA assigned number to Serpasil-apresoline. Format is nnnnnn.

Product Number - 002
The FDA assigned number to identify Serpasil-apresoline. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Approved Prior to Jan 1, 1982
The date Serpasil-apresoline was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Serpasil-apresoline. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Serpasil-apresoline is in. Format is RX, OTC, DISCN.

Applicant Full Name - Novartis Pharmaceuticals Corp
The full name of the firm holding legal responsibility for the new application of Serpasil-apresoline.

Serpasil-apresoline